000120667 001__ 120667
000120667 005__ 20240228145459.0
000120667 0247_ $$2doi$$a10.1007/s00259-017-3665-9
000120667 0247_ $$2pmid$$apmid:28280855
000120667 0247_ $$2pmc$$apmc:PMC5397661
000120667 0247_ $$2ISSN$$a0340-6997
000120667 0247_ $$2ISSN$$a1432-105X
000120667 0247_ $$2ISSN$$a1619-7070
000120667 0247_ $$2ISSN$$a1619-7089
000120667 0247_ $$2altmetric$$aaltmetric:17296129
000120667 037__ $$aDKFZ-2017-01093
000120667 041__ $$aeng
000120667 082__ $$a610
000120667 1001_ $$00000-0002-4492-4243$$aAfshar-Oromieh, Ali$$b0$$eFirst author
000120667 245__ $$aRepeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095.
000120667 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2017
000120667 3367_ $$2DRIVER$$aarticle
000120667 3367_ $$2DataCite$$aOutput Types/Journal article
000120667 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660303976_9214
000120667 3367_ $$2BibTeX$$aARTICLE
000120667 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120667 3367_ $$00$$2EndNote$$aJournal Article
000120667 520__ $$aProstate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies.Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with (131)I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years.The best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50% was achieved in 70.6% of the patients. The second and third therapies were significantly less effective. There was neither an association between the applied activity and PSA response or the time-to-progression. Hematologic toxicities were less prevalent but presented in a higher percentage of patients with increasing number of therapies. After hematologic toxicities, xerostomia was the second most frequent side effect and presented more often and with higher intensity after the second or third therapy.The first dose of RLT with (131)I-MIP-1095 presented with low side effects and could significantly reduce the tumor burden in a majority of patients. The second and third therapies were less effective and presented with more frequent and more intense side effects, especially hematologic toxicities and xerostomia.
000120667 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120667 588__ $$aDataset connected to CrossRef, PubMed,
000120667 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b1
000120667 7001_ $$aZechmann, Christian$$b2
000120667 7001_ $$aArmor, Thomas$$b3
000120667 7001_ $$aMier, Walter$$b4
000120667 7001_ $$aSpohn, Fabian$$b5
000120667 7001_ $$aDebus, Nils$$b6
000120667 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b7$$udkfz
000120667 7001_ $$aBabich, John$$b8
000120667 7001_ $$aKratochwil, Clemens$$b9
000120667 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-017-3665-9$$gVol. 44, no. 6, p. 950 - 959$$n6$$p950 - 959$$tEuropean journal of nuclear medicine and molecular imaging$$v44$$x1619-7089$$y2017
000120667 909CO $$ooai:inrepo02.dkfz.de:120667$$pVDB
000120667 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4492-4243$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120667 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000120667 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000120667 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120667 9141_ $$y2017
000120667 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120667 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120667 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120667 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120667 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120667 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000120667 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120667 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120667 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120667 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120667 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120667 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120667 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000120667 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000120667 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000120667 980__ $$ajournal
000120667 980__ $$aVDB
000120667 980__ $$aI:(DE-He78)E060-20160331
000120667 980__ $$aI:(DE-He78)C060-20160331
000120667 980__ $$aUNRESTRICTED